Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Oct;72(4):1004–1006. doi: 10.1038/bjc.1995.450

Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?

L Lennard 1, J Welch 1, J S Lilleyman 1
PMCID: PMC2034028  PMID: 7547211

Abstract

As part of a programme assessing the pharmacokinetics of oral thiopurines given for lymphoblastic leukaemia, we assayed intracellular metabolites of mercaptopurine in children from all over the United Kingdom who were given a standard dose of the drug. The metabolites we measured, thioguanine nucleotides and methylmercaptopurines, are products of two competing metabolic pathways and would be expected to show an inverse correlation. A total of 327 children from 17 centres in the UK were studied. All were on the same therapeutic schedule of mercaptopurine. All had been on an unattenuated full protocol-directed dose (at least 75 mg m-2) for a minimum of 7 days before assay. There was a very wide variation in the concentration of the two metabolites measured; the thioguanine nucleotides ranged from 0 to 1255 pmol per 8 x 10(8) red cells (median 289, lower quartile 210, upper quartile 377) and the methylmercaptopurine metabolites ranged from 0 to 46.3 nmol per 8 x 10(8) red cells (median 5.18, lower quartile 2.31, upper quartile 11.59). The anticipated negative correlation was not apparent, but the ratio between the two was not randomly distributed. No child had both metabolite concentrations in the upper quartiles, but in 32 (10%) children the concentration of both metabolites was in the lower quartile. Of the 32, only one metabolite was detected in four and none at all in six. The most likely explanation for these findings is that a minority of children with lymphoblastic leukaemia fail to take oral mercaptopurine either totally or intermittently. The extent of the problem is unknown, but we suspect it may be clinically important in at least 10% of patients.

Full text

PDF
1004

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chessells J. M., Bailey C., Richards S. M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet. 1995 Jan 21;345(8943):143–148. doi: 10.1016/s0140-6736(95)90164-7. [DOI] [PubMed] [Google Scholar]
  2. Davies H. A., Lennard L., Lilleyman J. S. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ. 1993 May 8;306(6887):1239–1240. doi: 10.1136/bmj.306.6887.1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davies H. A., Lilleyman J. S. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia. Cancer Treat Rev. 1995 Mar;21(2):93–103. doi: 10.1016/0305-7372(95)90022-5. [DOI] [PubMed] [Google Scholar]
  4. Lennard L., Gibson B. E., Nicole T., Lilleyman J. S. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993 Nov;69(5):577–579. doi: 10.1136/adc.69.5.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  6. Lennard L., Singleton H. J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992 Nov 27;583(1):83–90. doi: 10.1016/0378-4347(92)80347-s. [DOI] [PubMed] [Google Scholar]
  7. Lilleyman J. S., Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 1994 May 14;343(8907):1188–1190. doi: 10.1016/s0140-6736(94)92400-7. [DOI] [PubMed] [Google Scholar]
  8. Macdougall L. G., McElligott S. E., Ross E., Greeff M. C., Poole J. E. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance. Ther Drug Monit. 1992 Oct;14(5):371–375. doi: 10.1097/00007691-199210000-00005. [DOI] [PubMed] [Google Scholar]
  9. McLeod H. L., Lin J. S., Scott E. P., Pui C. H., Evans W. E. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994 Jan;55(1):15–20. doi: 10.1038/clpt.1994.4. [DOI] [PubMed] [Google Scholar]
  10. Rivera G. K., Pinkel D., Simone J. V., Hancock M. L., Crist W. M. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med. 1993 Oct 28;329(18):1289–1295. doi: 10.1056/NEJM199310283291801. [DOI] [PubMed] [Google Scholar]
  11. Shope J. T. Medication compliance. Pediatr Clin North Am. 1981 Feb;28(1):5–21. doi: 10.1016/s0031-3955(16)33959-1. [DOI] [PubMed] [Google Scholar]
  12. Smith S. D., Rosen D., Trueworthy R. C., Lowman J. T. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979 Jan;43(1):169–173. doi: 10.1002/1097-0142(197901)43:1<169::aid-cncr2820430125>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  13. Tebbi C. K., Cummings K. M., Zevon M. A., Smith L., Richards M., Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer. 1986 Sep 1;58(5):1179–1184. doi: 10.1002/1097-0142(19860901)58:5<1179::aid-cncr2820580534>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES